Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib
- First Online:
- Cite this article as:
- Heigener, D.F. & Reck, M. Adv Therapy (2011) 28: 126. doi:10.1007/s12325-010-0096-4
- 163 Views
Epidermal growth factor receptor (EGFR)-activating mutations in non-small cell lung cancer (NSCLC) are molecular targets for treatment with gefitinib and erlotinib, often resulting in improved response and prolonged progression-free survival. Resistance to these drugs, which develops during treatment, is a problem of paramount importance. Several mechanisms of “acquired resistance” have been discovered and treatments for this specific entity are on the horizon.